# EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Study · id `cardio:ct-nct07064473` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07064473](<https://clinicaltrials.gov/study/NCT07064473>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07064473

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11800 participants.

## Technical summary

Registry record NCT07064473. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-22 (actual); primary completion 2029-12-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 11800 participants (planned count; ClinicalTrials.gov record NCT07064473, source copy `cardio:ctgov-nct07064473-2026-11-12`, retrieved 2026-11-18)
- Started: 2025-07-22 (actual) (ClinicalTrials.gov record NCT07064473, source copy `cardio:ctgov-nct07064473-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2029-12-14 (anticipated) (ClinicalTrials.gov record NCT07064473, source copy `cardio:ctgov-nct07064473-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-12-21 (anticipated) (ClinicalTrials.gov record NCT07064473, source copy `cardio:ctgov-nct07064473-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; India; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Portugal; Puerto Rico; Romania; Saudi Arabia; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07064473, source copy `cardio:ctgov-nct07064473-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07064473-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypertension
- Condition: Cardiovascular Diseases
- Intervention (Drug): Vicadrostat
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo matching Vicadrostat
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: e6512b246efe37a59d8d22c46706b760d7b108c320caff2957d84c5555040912
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
